Download PDF

1. Company Snapshot

1.a. Company Description

ClearPoint Neuro, Inc.operates as a medical device company primarily in the United States.The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance.


It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite.It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco.The company was formerly known as MRI Interventions, Inc.


and changed its name to ClearPoint Neuro, Inc.in February 2020.ClearPoint Neuro, Inc.


was incorporated in 1998 and is headquartered in Solana Beach, California.

Show Full description

1.b. Last Insights on CLPT

ClearPoint Neuro's recent performance was driven by several positive factors. The company's Q2 2025 results showcased record revenue and substantial cash infusion, highlighting its 'Fast. Forward.' strategy. Additionally, the FDA clearance for the ClearPoint Prism Neuro Laser Therapy System to include 1.5T MRI guidance expanded its market opportunity. Partnership milestones, including commercial infusions in the US and progress in gene therapy delivery, also contributed to growth. Furthermore, the appointment of Dr. Paul Larson as Chief Medical Officer and positive data from partner uniQure's Huntington's Disease trials have bolstered the company's prospects.

1.c. Company Highlights

2. ClearPoint Neuro's Strategic Merger and Q3 2025 Earnings Review

ClearPoint Neuro reported revenue of $8.9 million for the third quarter of 2025, marking a 9% increase from the same period in 2024. The company's biologics and drug delivery revenue remained relatively consistent at $4.4 million, while neurosurgery navigation therapy revenue grew 20% to $3.4 million. Capital equipment and software revenue also saw a significant increase of 25% to $1 million. The earnings per share (EPS) came in at -$0.21, slightly missing estimates of -$0.2. Analysts estimate next year's revenue growth at 38.3%, indicating a positive outlook for the company's future performance.

Publication Date: Nov -20

📋 Highlights
  • Merger Access to $500M Market:: Acquisition of IRRAS grants entry into intracerebral hemorrhage treatment market, valued at $0.5 billion.
  • Q3 2025 Revenue Growth:: Revenue rose to $8.9 million (+9% YoY), driven by 20% growth in neurosurgery navigation therapy ($3.4 million) and 25% increase in capital equipment/software ($1 million).
  • $10 Billion Neuro Drug Delivery Market:: "Essential Everywhere" strategy targets a $10+ billion neuro drug delivery market, with ClearPoint holding under 10% share.
  • 2026 Revenue Forecast:: Merged entity projects $54–$60 million revenue in 2026, up from 2025’s narrowed $36–$38 million forecast.
  • Long-Term $500M Revenue Vision:: Aims to merge two strategies into a $500 million revenue company with 70%+ gross margins by capturing incremental market shares.

Segment Performance and Growth Drivers

The revenue growth was driven by the company's neurosurgery navigation therapy and capital equipment and software segments. The biologics and drug delivery segment remained stable, indicating a steady demand for ClearPoint's products in this area. The company's new product launches and expanding commercial team are expected to drive further growth in the coming quarters.

Merger with IRRAS and Expanded Market Opportunities

The merger with IRRAS is expected to give ClearPoint access to a large existing market in intracerebral hemorrhage treatment, worth approximately $0.5 billion. The combined entity will also gain operational scale with an expansive commercial team, including marketing, sales, and clinical specialists. This move is part of ClearPoint's strategy to build a new market around its ClearPoint drug delivery ecosystem, which is considered the gold standard in this space.

Valuation and Growth Prospects

With a P/S Ratio of 11.84 and an expected revenue growth rate of 38.3% next year, the company's valuation appears to be reasonable. However, the negative EPS and high P/B Ratio of 20.02 indicate that the stock may be overvalued. The company's long-term vision is to generate $500 million in revenue with a single commercial and operational infrastructure. If achieved, this could lead to significant returns for investors.

Operational Efficiency and Cash Flow

The company's pro forma business for 2026 is expected to have a gross margin of 70% plus, with the IRRAS system being a razor-razorblade system with a high percentage of disposable revenue. ClearPoint expects to reduce its burn rate meaningfully and significantly over time, with some integration costs in the first quarter. The establishment of a new CRO site will also create new revenue streams and opportunities for growth.

3. NewsRoom

Card image cap

ClearPoint Neuro Completes Acquisition of IRRAS

Nov -20

Source: accessnewswire.com

Card image cap

ClearPoint Neuro, Inc. (CLPT) Q3 2025 Earnings Call Transcript

Nov -12

Source: seekingalpha.com

Card image cap

ClearPoint Neuro: CRO Facility Should Reaccelerate Growth

Nov -12

Source: seekingalpha.com

Card image cap

ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Lags Revenue Estimates

Nov -07

Source: zacks.com

Card image cap

ClearPoint Neuro Reports Third Quarter 2025 Results

Nov -06

Source: accessnewswire.com

Card image cap

ClearPoint Neuro Announces Agreement to Acquire IRRAS

Nov -06

Source: accessnewswire.com

Card image cap

ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2025

Nov -05

Source: accessnewswire.com

Card image cap

ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles

Oct -07

Source: accessnewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.61%)

6. Segments

Biologics and Drug Delivery - Services and License

Expected Growth: 9.95%

Strong demand for biologics and drug delivery services, driven by increasing prevalence of chronic diseases and growing need for innovative treatments. ClearPoint Neuro's expertise in neurosurgical navigation and therapy delivery enables precise and minimally invasive procedures, fueling 9.95% growth. Partnerships and licensing agreements with pharmaceutical and biotech companies further accelerate growth.

Functional Neurosurgery Navigation and Therapy - Disposable Products

Expected Growth: 9.27%

Strong demand for minimally invasive neurosurgical procedures, increasing adoption of ClearPoint Neuro's navigation and therapy systems, and growing awareness of functional neurosurgery benefits drive 9.27% growth. Additionally, advancements in disposable product technology, expanding indications for neurosurgical interventions, and strategic partnerships contribute to the segment's rapid expansion.

Biologics and Drug Delivery - Disposable Products

Expected Growth: 9.27%

ClearPoint Neuro's Biologics and Drug Delivery - Disposable Products segment growth of 9.27% is driven by increasing demand for minimally invasive neurosurgical procedures, advancements in gene therapy, and growing adoption of disposable products in neurointerventions, coupled with the company's strong R&D pipeline and strategic partnerships.

Capital Equipment and Software - Services

Expected Growth: 9.03%

ClearPoint Neuro's 9.03% growth in Capital Equipment and Software - Services is driven by increasing adoption of minimally invasive neurosurgical procedures, rising demand for precision-guided therapies, and expansion into new markets. Additionally, the company's innovative product offerings, strategic partnerships, and growing installed base of biopsies and laser ablation systems contribute to its growth momentum.

Functional Neurosurgery Navigation and Therapy - Services

Expected Growth: 10.43%

ClearPoint Neuro's 10.43% growth in Functional Neurosurgery Navigation and Therapy Services is driven by increasing adoption of minimally invasive procedures, advancements in neuro-navigation technology, growing demand for precise lesioning and ablation, and expanding indications for neurosurgical interventions, such as epilepsy and Parkinson's disease treatments.

Capital Equipment and Software - Systems and Software Products

Expected Growth: 9.03%

ClearPoint Neuro's 9.03% growth in Capital Equipment and Software - Systems and Software Products is driven by increasing adoption of minimally invasive neurosurgical procedures, growing demand for precision-guided therapies, and expansion into new markets. Additionally, advancements in AI-powered navigation and planning software, and strategic partnerships with hospitals and research institutions, contribute to the segment's growth.

7. Detailed Products

Neuro Navigation

A surgical navigation system that provides real-time visualization and guidance during neurosurgical procedures.

Intraoperative Imaging

A suite of imaging technologies that provide real-time visualization during neurosurgical procedures.

Stereotactic Systems

A range of systems for stereotactic neurosurgery, including frame-based and frameless options.

Neurodiagnostics

A range of diagnostic tools for neurologists and neurosurgeons, including EEG and EMG systems.

Surgical Planning Software

Advanced software for pre-operative planning and simulation of neurosurgical procedures.

8. ClearPoint Neuro, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

ClearPoint Neuro, Inc. faces moderate threat from substitutes, as there are limited alternative treatments for brain disorders, but ongoing research and development may lead to new substitutes in the future.

Bargaining Power Of Customers

Customers have limited bargaining power due to the specialized nature of ClearPoint Neuro, Inc.'s products and services, which are critical for treating brain disorders.

Bargaining Power Of Suppliers

Suppliers of raw materials and components have moderate bargaining power, as ClearPoint Neuro, Inc. relies on a few key suppliers, but there are alternative sources available.

Threat Of New Entrants

The threat of new entrants is low due to the high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise.

Intensity Of Rivalry

The medical device industry is highly competitive, with several established players, and ClearPoint Neuro, Inc. faces intense rivalry in the market for brain disorder treatments.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 32.88%
Debt Cost 3.95%
Equity Weight 67.12%
Equity Cost 8.81%
WACC 7.21%
Leverage 48.99%

11. Quality Control: ClearPoint Neuro, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Rapid Micro Biosystems

A-Score: 4.3/10

Value: 7.2

Growth: 3.6

Quality: 3.8

Yield: 0.0

Momentum: 10.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
ClearPoint Neuro

A-Score: 4.2/10

Value: 6.0

Growth: 4.4

Quality: 4.1

Yield: 0.0

Momentum: 9.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
NeuroOne Medical Technologies

A-Score: 3.7/10

Value: 6.8

Growth: 6.1

Quality: 4.2

Yield: 0.0

Momentum: 4.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Accelerate Diagnostics

A-Score: 3.5/10

Value: 10.0

Growth: 5.6

Quality: 5.0

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Cytek Biosciences

A-Score: 3.4/10

Value: 6.3

Growth: 7.0

Quality: 3.8

Yield: 0.0

Momentum: 1.5

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Pulmonx

A-Score: 3.1/10

Value: 9.0

Growth: 4.6

Quality: 4.2

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

13.54$

Current Price

13.54$

Potential

-0.00%

Expected Cash-Flows